Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Angi Inc (ANGI) vs Pfizer Inc (PFE) Price & Performance

Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Angi Inc vs Pfizer Inc — how do they compare? Angi Inc trades at $4.4 (market cap $182.30M), while Pfizer Inc trades at $26.21 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 832.3× Angi Inc's market cap, and Pfizer Inc pays a 6.46% dividend while Angi Inc pays none. Which is the better fit depends on your goals.

ANGIPFE
Market Cap
$182.30M$151.73B
Sector
MediaHealth
52-Week High
$18.46$28.56
52-Week Low
$4.49$23.60
Enterprise Value
$392.07M$203.22B
Volume
29,869,932
Dividend Yield
6.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Angi Inc

ANGI trades at $4.59, down 5.17% on the day, reflecting ongoing operational challenges. The stock is in a bearish technical trend, with revenue declining from $1.03B in 2025 to a projected $993M in 2026. Recent Q2 2026 earnings missed expectations significantly, with an EPS of -$5.7 versus an expected $0.1333, highlighting deep profitability issues. Negative net income margins and cash flow concerns persist, though valuation ratios like P/S of 0.19 and P/B of 0.27 appear low.

The outlook remains cautious due to accelerating user churn, revenue declines, and lack of clear catalysts. Analyst consensus is a Hold with a $7.00 price target, but risks include ongoing fraud investigations, competitive pressures, and negative cash flow trends. Upside potential exists if the company stabilizes its platform, but current fundamentals suggest continued headwinds for shareholder value.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Angi Inc

Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair

Read more on ANGI

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE